Navigation Links
The Astellas European Foundation Winner of Transplantation Grant 2011 Announced

GLASGOW, Scotland, September 7, 2011 /PRNewswire/ --

The Astellas European Foundation is delighted to announce the winner of the 2011 Transplantation Grant:

Dr Christian Toso of the University of Geneva, Switzerland

Last evening, the University's team, led by Dr Toso, received the grant of US$ 300,000 to support work on their project entitled 'Towards a tailored immuno-suppression after liver transplantation for hepatocellular carcinoma' at the Astellas European Foundation Award presentation.

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Vice President Medical Affairs and Health Economics for Astellas Pharma Europe Ltd. commented, "We received many entries of a very high standard which covered a broad range of topics across Europe.  In the face of very strong competition the Jury chose Dr Toso's research based on its potential impact on clinical practice.  The team's aim is to tailor immunosuppressive strategy for individual patients with hepatocellular carcinoma. It is very exciting and, in the future, their results could possibly be applied to other cancers."

At the Award Presentation Event in Glasgow, UK, the Astellas European Foundation emphasised their continued and long term commitment to research and development in the field of transplant medicine.

Dr Toso said, "We thank the Astellas European Foundation for its generous support. Although liver transplantation is the most efficient treatment for patients with early  unresectable hepatocellular carcinoma, some 10% of recipients still experience recurrence after transplantation. The aim of our study is to define the ideal immunosuppression strategy, both clearing cancer cells and preventing rejection. Such a study has the potential to better tailor immunosuppression after liver transplantation for cancer, improve outcomes and qualify some currently excluded patients with more advanced HCCs for transplantation."

The Astellas European Foundation is a registered charity. It was established in 2005 with the  goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation Transplantation Grant supports basic medical and related scientific programmes which contribute to advancements in transplant medicine.  The winner of the grant was chosen by a Jury that includes independent European transplantation leaders.

Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, established in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 4,000 staff across these regions.

SOURCE Astellas European Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Monitoring (TDM) Market: Supplier Shares, Country ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... OAKS, Calif. , Nov. 25, 2015  Amgen ... a Biologics License Application (BLA) with the ... (FDA) for ABP 501, a biosimilar candidate to Humira ... first adalimumab biosimilar application submitted to the FDA and ... pathway. Sean E. Harper , M.D., executive ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... wellness consultation, has collaborated with Women’s Web – an online resource for ... topics on mental and emotional well-being relationship, life balance, stress, professional development, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... potentially more aggressive than those found on mammography, according to a study published ... of additional cancers not seen on mammography may necessitate a change in treatment. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... preparing the perfect dish and pleasing the palates of attendees is of the ... a dish to a seasonal get-together, give these recipes a try this holiday ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, ... again for its stellar workplace culture with the company’s Cincinnati office being named ... Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s 13th annual ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... Dr. John ... to learn more about hair loss treatment with the Capillus272™ Pro laser therapy cap. ... solution for thicker and fuller hair, without the need for surgery, prescription pills, or ...
Breaking Medicine News(10 mins):